The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
A 74-year-old male with diffuse large B-cell lymphoma, with an Ann Arbor stage IV-A, was submitted to immune-chemotherapy in 2014, with complete remission of the disease. Two years later, he presented with a left eye swelling leading to exophthalmos and blurred vision. A core biopsy was performed an...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2019/2845130 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547564392546304 |
|---|---|
| author | R. Palmieri F. Esposito F. Meconi V. M. Rapisarda L. Anemona G. Paterno S. Vaccarini D. Nasso L. Pupo M. Cantonetti |
| author_facet | R. Palmieri F. Esposito F. Meconi V. M. Rapisarda L. Anemona G. Paterno S. Vaccarini D. Nasso L. Pupo M. Cantonetti |
| author_sort | R. Palmieri |
| collection | DOAJ |
| description | A 74-year-old male with diffuse large B-cell lymphoma, with an Ann Arbor stage IV-A, was submitted to immune-chemotherapy in 2014, with complete remission of the disease. Two years later, he presented with a left eye swelling leading to exophthalmos and blurred vision. A core biopsy was performed and revealed a local relapse of the disease. He was considered unfit for intensive salvage chemotherapy and was treated with a combination of rituximab and lenalidomide. After six courses of rituximab plus lenalidomide, the patient showed complete remission and was submitted to maintenance therapy with lenalidomide. After 24 months since the start of lenalidomide monotherapy, we did not observe any progression. In this experience, rituximab plus lenalidomide, without radiotherapy, was a safe and effective therapeutic combination in an elderly patient with a localized relapse of DLBCL who was unfit to receive more aggressive therapies. |
| format | Article |
| id | doaj-art-3ede073b7311402381c58399f0395716 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-3ede073b7311402381c58399f03957162025-02-03T06:44:23ZengWileyCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/28451302845130The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell LymphomaR. Palmieri0F. Esposito1F. Meconi2V. M. Rapisarda3L. Anemona4G. Paterno5S. Vaccarini6D. Nasso7L. Pupo8M. Cantonetti9Fondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyFondazione Policlinico Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, ItalyA 74-year-old male with diffuse large B-cell lymphoma, with an Ann Arbor stage IV-A, was submitted to immune-chemotherapy in 2014, with complete remission of the disease. Two years later, he presented with a left eye swelling leading to exophthalmos and blurred vision. A core biopsy was performed and revealed a local relapse of the disease. He was considered unfit for intensive salvage chemotherapy and was treated with a combination of rituximab and lenalidomide. After six courses of rituximab plus lenalidomide, the patient showed complete remission and was submitted to maintenance therapy with lenalidomide. After 24 months since the start of lenalidomide monotherapy, we did not observe any progression. In this experience, rituximab plus lenalidomide, without radiotherapy, was a safe and effective therapeutic combination in an elderly patient with a localized relapse of DLBCL who was unfit to receive more aggressive therapies.http://dx.doi.org/10.1155/2019/2845130 |
| spellingShingle | R. Palmieri F. Esposito F. Meconi V. M. Rapisarda L. Anemona G. Paterno S. Vaccarini D. Nasso L. Pupo M. Cantonetti The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma Case Reports in Hematology |
| title | The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma |
| title_full | The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma |
| title_fullStr | The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma |
| title_full_unstemmed | The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma |
| title_short | The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma |
| title_sort | efficacy and safety of lenalidomide plus rituximab in an orbital relapse of diffuse large b cell lymphoma |
| url | http://dx.doi.org/10.1155/2019/2845130 |
| work_keys_str_mv | AT rpalmieri theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT fesposito theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT fmeconi theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT vmrapisarda theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT lanemona theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT gpaterno theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT svaccarini theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT dnasso theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT lpupo theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT mcantonetti theefficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT rpalmieri efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT fesposito efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT fmeconi efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT vmrapisarda efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT lanemona efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT gpaterno efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT svaccarini efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT dnasso efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT lpupo efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma AT mcantonetti efficacyandsafetyoflenalidomideplusrituximabinanorbitalrelapseofdiffuselargebcelllymphoma |